Pronto Diagnostics

The deal covers MNG's complete line of neurogenetic clinical RNA sequencing services, including complete transcriptome sequencing.

The Israeli molecular diagnostics company will use artificial intelligence and phenotypic analysis to increase the diagnostic rate of its genetic tests.

By Molika Ashford
In the hunt for the genetic causes of hearing loss in local populations, researchers at Tel Aviv University have taken up targeted genomic capture and deep sequencing to root out causative mutations.

Pronto will begin offering the test to the private payor market and begin the regulatory process to make the test available to the publicly funded Israeli HMO market.

Signal Genetics' CEO J said the deal "represents our initial entry into the international market with MyPRS and strong interest among both laboratories and physicians outside the United States in providing broader access to this novel technology."

Starting in November, Pronto Diagnostics plans to begin marketing in Israel Epigenomics' Septin 9-based test for early detection of colorectal cancer

Pronto, based in Tel Aviv, is the first distributor for Epi proColon outside of Germany, where Epigenomics is headquartered.

Pronto will begin marketing Epigenomics' Epi proColon test in November.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.